Factor IXa – Factor VIIIa complex (FIXa-FVIIIa)

The Factor IXa – Factor VIIIa complex, also known as the intrinsic tenase complex, is a critical multi-protein assembly in the blood coagulation cascade [1, 10]. It consists of the activated serine protease Factor IXa and its non-enzymatic cofactor Factor VIIIa, which assemble on negatively charged phospholipid surfaces, such as those of activated platelets, in the presence of calcium ions [10, 17]. This complex is responsible for the efficient activation of Factor X to Factor Xa, a rate-limiting step that leads to a "thrombin burst" necessary for stable clot formation [8, 15]. Deficiencies in either component lead to hemophilia (Hemophilia A for Factor VIII and Hemophilia B for Factor IX), while overactivity or gain-of-function mutations are linked to thrombotic disorders [3, 7, 14]. Modern therapeutic strategies include replacement of the individual factors or the use of bispecific antibodies like emicizumab, which mimics the bridging function of the complex to restore hemostasis in patients with hemophilia A [1, 3, 5].

Other names

Intrinsic tenase complexTenase complexFactor IXa/VIIIa complexFIXa-FVIIIa complexIntrinsic factor Xase

The complex functions as the intrinsic tenase, where Factor VIIIa acts as a cofactor to dramatically increase the catalytic efficiency of Factor IXa in activating Factor X [1, 17]. Drugs targeting this complex either replace the deficient components (Factor VIII or IX), inhibit the complex to prevent thrombosis (e.g., heparin), or utilize bispecific antibodies (e.g., emicizumab) to mimic the spatial bridging of Factor IXa and Factor X normally facilitated by Factor VIIIa [1, 3, 13].